This facility has been under construction since 2007 — but is good news, nonetheless, after the closures and layoffs in Ireland, of exactly one year ago, this month. This, from a local online pharma news report:
. . . .The US giant, known as Merck, Sharp & Dohme (MSD) outside North America, noted that construction on the facility at the existing Ballydine site began in September 2007 and since then 70 new high calibre roles have been created. This number could increase to 120 as new innovative medicines are developed at MSD and an additional 6 million euro investment is already in the planning phase to extend the new site. . . .
There are currently six new drugs in development at MSD Ballydine, including a cholesterol/type 2 diabetes combination and a treatment for hepatitis C. . . .
A glimmer of good news, eh?